Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2017 | review | Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017

American Society of Hematology 2016 annual meeting

Novel strategies in the management of lymphoma

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2017
Autor:
MD Daniel Heintel

Summary

At the last meeting of the American Society of Hematology (ASH), data on first-line treatment with obinutuzumab in indolent lymphoma, as well as promising data on the long-term observation of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, were presented.
In diffuse large B‑cell lymphoma (DLBCL), again, a more intensified treatment approach failed to improve patient survival. Moreover, and in contrast to indolent lymphoma, the use of obinutuzumab instead of rituximab (R) did not prove to be superior in DLBCL. However, data on lenalidomide maintenance, as well as data on novel agents in primary central nervous system lymphoma (PCNL), were presented. A survival benefit for R maintenance therapy could be shown in mantle cell lymphoma (MCL).

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017 Zur Ausgabe